PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Genet Med. Author manuscript; available in PMC 2013 July 12.
Published in final edited form as:
Published online 2012 January 5. doi:  10.1038/gim.2011.1
PMCID: PMC3709024
NIHMSID: NIHMS484059

Argininosuccinate Lyase Deficiency

SUMMARY

The urea cycle consists of six consecutive enzymatic reactions that convert waste nitrogen into urea. Deficiencies of any of these enzymes of the cycle result in urea cycle disorders (UCD), a group of inborn errors of hepatic metabolism that often result in life threatening hyperammonemia. Argininosuccinate Lyase (ASL) catalyzes the fourth reaction in this cycle resulting in the breakdown of argininosuccinic acid to arginine and fumarate. Argininosuccinate Lyase deficiency (ASLD) is the second most common UCD with a prevalence of ~1 in 70,000 live births. ASLD can manifest as either a severe neonatal onset form with hyperammonemia within the first few days after birth or as a late onset form with episodic hyperammonemia and/or long term complications that include liver dysfunction, neuro-cognitive deficits and hypertension. These long term complications can occur in the absence of hyperammonemic episodes implying that ASL has functions outside of its role in ureagenesis and the tissue specific lack of ASL may be responsible for these manifestations. The biochemical diagnosis of ASLD is typically established with elevation of plasma citrulline together with elevated argininosuccinic acid in the plasma or urine. Molecular genetic testing of ASL and assay of ASL enzyme activity are helpful when the biochemical findings are equivocal. However, there is no correlation between the genotype, or enzyme activity and clinical outcome. Treatment of acute metabolic decompensations with hyperammonemia involves discontinuing oral protein intake; supplementing oral intake with intravenous lipids and/or glucose, and use of intravenous arginine and nitrogen scavenging therapy. Dietary restriction of protein and dietary supplementation with arginine are the mainstays in long-term management. Orthotopic liver transplantation is best considered only in patients with recurrent hyperammonemia or metabolic decompensations resistant to conventional medical therapy.

Keywords: Argininosuccinic aciduria, Argininosuccinate Lyase, urea cycle, arginine, nitric oxide

INTRODUCTION

The urea cycle (Figure. 1) has two main functions: the detoxification of waste nitrogen into excretable urea and the de novo biosynthesis of arginine 1. Deficiencies of any of these enzymes of the cycle result in urea cycle disorders (UCDs), a group of inborn errors of hepatic metabolism that often result in life threatening hyperammonemia. The overall prevalence of UCDs is estimated to be of 1 in 8,200 in the United States 2.

Figure 1
The urea cycle

The deficiency of the enzyme argininosuccinate lyase (ASL; MIM 608310), an enzyme that cleaves argininosuccinate to fumarate and arginine results in an inborn error of ureagenesis termed Argininosuccinic Aciduria (OMIM 207900). Argininosuccinate lyase deficiency (ASLD) has an estimated prevalence of 1 in 70,000 live births 3 making it the second most common urea cycle disorder (UCD) 4. The first documented case of this condition was in 1958 where it was described as “a disease, probably hereditary, characterized by severe mental deficiency and a constant gross abnormality of amino acid metabolism” 5.

CLINICAL CHARACTERISTICS

The clinical presentation of ASLD is variable. The two most common forms are a severe neonatal onset form and a late onset form.

Severe neonatal onset form

The clinical presentation of the severe neonatal onset form is identical to that of other UCDs and is characterized by hyperammonemia within the first few days of life. Newborns typically appear healthy for the first 24 hours but within the next few days develop vomiting, lethargy, and hypothermia and refuse to accept feeds 3. Tachypnea and respiratory alkalosis are early findings that suggest hyperammonemia. A failure to recognize and treat the defect in ureagenesis leads to worsening lethargy, seizures, coma, and death. The findings of hepatomegaly and trichorrhexis nodosa (coarse and friable hair) at this early stage are the only clinical findings that may suggest the diagnosis of ASLD 3.

Late onset form

The manifestations of the late onset form range from episodic hyperammonemia (triggered by acute infection or stress or by non-compliance with dietary restrictions and/or medication) to cognitive impairment, behavioral abnormalities, and/or learning disabilities in the absence of any documented episodes of hyperammonemia 3.

Long Term Complications

While manifestations secondary to hyperammonemia are common to all urea cycle disorders, many individuals with ASLD present with a more complex and unique clinical phenotype. There are increased incidences of (1) neurocognitive deficiencies, (2) hepatic disease, and (3) systemic hypertension in patients with ASLD. These manifestations appear to be unrelated to the severity or duration of hyperammonemic episodes 68.

Neurocognitive deficiencies

In a cross-sectional study of individuals with UCDs, it was observed that patients with ASLD had a significant increase in disabilities and neurologic abnormalities as compared to persons with OTC deficiency 4. Individuals with ASLD also had an increased incidence of attention deficit hyperactivity disorder (ADHD), developmental disability (intellectual disability, behavioral abnormalities, and/or learning disability), and seizures compared to persons with all other UCDs 4. In recent long term outcome studies in individuals with ASLD, intellectual disability, developmental delay, seizures and abnormal electroencephalograms were noted even in those without metabolic decompensations 8, 9. However, it is to be noted that while the neurocognitive deficits are more common in ASLD than in other UCDs, they are not universally present.

Hepatic Disease

Liver disease in individuals with ASLD also appears to be independent of the defect in ureagenesis. Hepatic involvement ranges from hepatomegaly to elevations of liver enzymes to severe liver fibrosis 4, 7, 10, 11. Liver involvement has been noted even in individuals treated with protein restriction and arginine supplementation who had not experienced significant hyperammonemia 7, 9. At present no biochemical or molecular features help predict liver dysfunction in people with ASL deficiency. Given the potential direct toxicity of argininosuccinic acid on hepatocytes, lowering of the argininosuccinate levels in plasma (a reflection of its production by the liver) may have potential benefit, though this has not yet been proven.

Hypertension

Recently, it has been noted that hypertension is over-represented in persons with ASLD 12. Usually no secondary causes of hypertension are detected, suggesting that this finding is related to ASLD.

Electrolyte imbalances

Some individuals develop electrolyte imbalances such as hypokalemia [Author, personal observation]. The hypokalemia is observed even in individuals who are not treated with sodium phenylbutyrate. The etiology is unclear; increased renal wasting has been suggested.

Other Manifestations

Trichorrhexis nodosa is characterized by nodular swellings of the hair shaft accompanied by frayed fibers and loss of cuticle. About half of individuals with ASLD have an abnormality of the hair manifest as dull, brittle hair surrounded by areas of partial alopecia 13 as either an early or late manifestation. Normal hair contains 10.5% arginine by weight; hair that is deficient in arginine as a result of ASLD is weak and tends to break.

BIOCHEMICAL CHARACTERISTICS

Elevated plasma ammonia with respiratory alkalosis is the classical finding observed during periods of metabolic decompensations. Plasma amino acid analyses typically reveal elevated citrulline levels in the range of 100–300 μmol/L 3. The accumulation of argininosuccinic acid (and its anhydrides), the substrate upstream of the metabolic block is the biochemical hallmark of ASLD. The typical levels observed in ASLD patients range between 50 and 110 μmol/L in the plasma, and >10,000 μmol/g of creatinine in the urine 8. Elevations of alanine, glutamine and glycine that imply deficiency of nitrogen disposal by conversion to urea are also commonly observed in the plasma amino acid profile. While typically the orotic acid excretion is in the normal ranges, orotic aciduria may be observed in ASLD 14,15. The impaired recycling of ornithine seems to contribute to the increase in carbamoyl phosphate leading to overproduction of orotic acid 14.

MOLECULAR CHARACTERISTICS

Normal Allelic Variants

The human ASL gene cloned in 1986 is located on chromosome 7q11.21 16. ASL consists of 17 exons with the first exon encoding for the 5′ UTR 17. A pseudogene ψ ASL2 was recently mapped in a region ~3 Mb upstream of ASL. The pseudogene includes intron 2, exon 3, and part of intron 3 of ASL 17. The ASL gene has now been identified in a variety of species including bacteria, Saccharomyces, algae, amphibia, rat, and human18. In humans, the protein is expressed predominantly in the liver but is also expressed in most other tissues such as fibroblasts, kidney, heart, brain, muscle, pancreas, and red blood cells.

Normal gene product

ASL cDNA encodes a deduced protein of 464 amino acids with a predicted molecular mass of 52 kD. The active enzyme is a homotetramer of four identical subunits with a molecular mass of 208 kD with four active sites in each tetramer 19. In addition to its role in ureagenesis, ASL is the only enzyme in the body that is capable of generating arginine. The expression pattern in a wide variety of tissues is likely intended to meet the need for arginine synthesis in these tissues.

ASL belongs to a super family of enzymes that have homologous motifs and catalyze similar cleavages with the release of fumarate as one of the products. Of all the enzymes in this family, ASL is most closely related to δ crystallin, a protein found in abundance in the lens of birds and reptiles 2022.

Abnormal allelic variants

ASLD is caused by many heterogeneous mutations in the ASL gene. The enzymatic activity of ASL requires assembly of four ASL monomers to form a homotetramer. Hence, the phenotypic consequences of a specific mutation are dependent on the mutation on the other allele and their ability to complement one another. The pathogenic mutations include nonsense and missense mutations, insertions, deletions, and those affecting mRNA splicing. Mutations are scattered throughout the gene; however, exons 4, 5, and 7 appear to be mutational hotspots 17, 23. While most of the pathogenic alterations are ‘private mutations’ in the families, there are three mutations with a founder effect.

  • The c.1153C>T variant, the founder mutation in the Finnish population, is associated with residual ASL enzyme activity as measured by the incorporation of [14C] citrulline into proteins 24.
  • Two founder mutations are present in people of Arab ancestry from the Kingdom of Saudi Arabia: The c.1060C>T change that results in a premature stop codon is responsible for approximately 50% of the ASL mutations in this population 25 while the other, c.346C>T is common but the proportion of individuals with this mutation is not known.

Abnormal gene product

Mutations in ASL lead to enzyme with reduced or absent catalytic activity.

MOLECULAR PATHOGENESIS

It is unlikely that elevated plasma ammonia is the only toxic compound in ASLD. The neuro-cognitive deficiencies can be observed even in the absence of hyperammonemia and liver dysfunction and hypertension occur seem unrelated to metabolic decompensations 8, 9, 12. These support the hypothesis that the phenotype in ASLD is likely due to a combination of the increase in argininosuccinic acid that is upstream of the block along with decreased endogenous synthesis of arginine that parsimoniously may lead to a decrease in arginine metabolites in various tissues.

Arginine is a semi-essential amino acid. The sources of arginine are exogenous from the diet and endogenous from the breakdown of proteins and synthesis from citrulline 26. In healthy adults, the level of endogenous synthesis (which is dependent on ASL) is sufficient to meet the arginine requirements of the body, thus making arginine a non-essential amino acid. However, in situations of catabolic stress, renal or intestinal dysfunction the endogenous arginine production is not commensurate with metabolic requirements and the body is dependent on exogenous sources for arginine.

The arginine generated in the liver, the major site of arginine metabolism, is converted to urea and ornithine. The liver does not contribute to the circulating pool of arginine. Approximately 60% of net synthesis of arginine in adult mammals occurs in the kidney, where citrulline is extracted from the blood and converted to arginine by the action of the enzymes argininosuccinate synthase (ASS) and ASL, located in the proximal tubules 27. However, many other tissues and cell types also contain both these enzymes for generating arginine from citrulline 28. In ASL deficiency, arginine becomes an essential amino acid because all cells and tissues are deficient in the enzyme ASL.

Arginine is the precursor compound for synthesis of many biologically important compounds including urea, nitric oxide (NO), polyamines, proline, glutamate, creatine, and agmatine (Figure 2). With deficiency of the ASL enzyme and the resulting deficiency in the amino acid arginine, one could hypothesize that there would also be deficiency of nitric oxide and other metabolites for which it is a precursor. However, ASLD patients are supplemented with arginine and hence theoretically, should not be deficient for its metabolites. The “arginine paradox”, describes the observation that despite apparently saturating intracellular levels of arginine, exogenously administered L-arginine is able to increase NO production. This important paradox suggests that L-arginine availability at the site of NO production may be the limiting factor 29, 30. Thus, it has been hypothesized that compartmentalization and intracellular metabolite channeling underlies the “arginine paradox” that distinguishes the extracellular from the intracellular pools of arginine.

Figure 2
Metabolic fates of arginine

A hypomorphic mouse model of Asl deficiency demonstrates multi-organ dysfunction including hypertension consistent with systemic NO deficiency 31. The mice have decreased NO production as evidenced by by a significant decrease in S-nitrosylation and/or nitrite in heart and other tissues. Corroboratively, NO production in patients with ASLD is lower as compared to those with OTC or ASS deficiency 31, 32. Dynamic measurements of metabolite fluxes using stable isotopes in both ASLD patients as well as in ASA mouse model, reveal a decreased NO flux 31. We have recently shown that there is a structural requirement of ASL for channeling of arginine into a protein complex necessary for NO production and hence ASLD leads to decrease of NO at the level of tissue and organism 31.

Depletion of arginine as substrate for NO synthesis also has the effect of causing increase free radical production due to uncoupling of Nitric Oxide Synthase 33. Increase in free radical production results in tissue damage with the brain being particularly sensitive to both direct and indirect effects of free radicals mediated by increases in intracellular free Ca2+ and/or excitatory amino acids 34. Free radicals could also interact with argininosuccinic acid in ASLD to form guanidinosuccinic acid, a cellular and neuronal toxin 3537. These begin to explain the unique clinical findings we see in ASA and as such could help in correlating genotype-phenotype long term outcome leading to optimization of the current treatment.

DIAGNOSIS

Newborn screening

All 50 states in the US include ASLD in their newborn screening programs [National Newborn Screening Status Report 2011]. Citrulline, assayed by tandem mass spectroscopy, is the metabolite used for detection of ASLD. Elevation of citrulline can also be seen with citrullinemia type 1 (ASS deficiency), citrullinemia type 2 (citrin deficiency) and pyruvate carboxylase deficiency; hence, confirmation of the diagnosis of ASL deficiency rests on further biochemical, molecular and or enzymatic testing.

Biochemical Testing

Confirmation of a clinical suspicion of ASLD or an abnormal newborn screen result is typically accomplished by plasma amino acid analyses that reveal elevated citrulline levels (in the range of 100–300 μmol/L) and the biochemical hallmark of increased argininosuccinic acid in the plasma and /or urine.

Molecular Genetic Testing

ASL is the only gene in which mutations are known to be associated with ASLD.

Sequence analysis of the coding region of ASL detects mutations in about 90% of individuals with the clinical and biochemical diagnosis of ASLD.

Deletion/duplication analysis

Though array comparative genomic hybridization-based assays have recently become available to detect deletions or duplications of ASL, no data are available on the frequency of these rearrangements in ASLD.

Targeted mutation analysis

The ASL c.1153C>T variant accounts for approximately 60% of mutations in the Finnish population and is offered on a clinical basis in Finland 38.

Enzymatic activity testing

ASL enzyme activity can be measured in cell homogenates from a flash-frozen liver biopsy or, more conveniently, from skin fibroblasts or red blood cells by one of two methods:

  • ‘Forward reaction’: addition of the substrate argininosuccinate followed by flurometric measurement of the product fumarate 24.
  • ‘Reverse reaction’: addition of the substrates 14C fumarate and unlabelled arginine followed by assay of the product 14C argininosuccinate.

The residual in vitro ASL enzyme activity as measured by these direct methods does not seem to correlate with the clinical severity and hence alternate indirect assays have been evaluated8.

The citrulline incorporation test is an indirect in vivo method of assessing the ASL activity in fibroblast cell cultures. Incorporation of 14C from L-[ureido-14C]citrulline and 3H from L-[3,4,5-3H(N)]-leucine into acid-precipitable material has been shown in at least one longitudinal study to be more sensitive in detecting residual ASL enzyme activity than the direct ASL enzyme activity assay performed on cell lysates. This assay hence is reported to have better correlation with the phenotype 8. However, because the citrulline incorporation test involves a skin biopsy and because the differences in results of this test compared to the results of the direct ASL enzyme assay were not significant, it is debatable as to whether this test is of value in determining the prognosis in a given individual with ASL deficiency.

Prenatal Diagnosis

If the mutations in the ASL gene are known, prenatal diagnosis can be performed by mutational analysis on either chorionic villous tissue or the amniocytes 39. Elevated levels of argininosuccinic acid in the amniotic fluid can also reliably detect affected fetuses 40, 41, 42. Analysis of enzyme activity by either direct methods from chorionic villus tissue or amniocytes or indirect methods such as 14C-citrulline incorporation in uncultured chorionic villus samples, have been successfully performed24, 43. Due to the limited amount of data available on the enzymatic analysis and argininosuccinic acid levels in the amniotic fluid, the sensitivity of these tests are not known. Moreover, the enzyme assays are available only at few specialized laboratories thus precluding their use in clinical settings.

Genotype-phenotype Correlation

The number of reported mutations is quite small compared to other urea cycle defects, as molecular genetic studies are not essential for the diagnosis 17, 23. In general, there has been a poor correlation between the residual enzymatic activity and severity of clinical phenotype. In vivo [14C] citrulline uptake has been reported to show better correlation with clinical phenotype in a single study but this has not been yet replicated in larger cohort of patients 23. Recently, mutant ASL proteins were studied in an in vitro bacterial enzymatic assay44 and corroborated with data from the clinical enzymatic testing. As observed with other methods, limited correlation was found between the patients’ clinical phenotype and the in vitro enzyme activity.

It is possible that the lack of correlation stems from a combination of decreased sensitivity of the current enzymatic assays as well as the fact the different mutations may allow for complementation in the tetramer. In order to study these variables, different mutant alleles were characterized by evaluating growth of yeast deletion mutants in arginine free media45. This method can detect low levels of residual activity and can assess the effect of different allelic complementation. This model was able to demonstrate that patients with late onset form of ASLD harbor either significant residual activity or allow for intragenic complementation. In these late onset ASLD patients, at least one active site was formed in the hybrid tetramer or the mutations partially stabilized each other 18, 45. The drawback of the assay is its inability to study the effect of the patient’s genetic background on enzyme activity. Continued characterizations of different allelic combinations will allow further correlation between clinical phenotype and the molecular changes.

MANAGEMENT

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs of an individual diagnosed with argininosuccinate lyase (ASL) deficiency the following evaluations are recommended: 1) complete neuro-cognitive evaluation, 2) evaluation for evidence of hepatic involvement such as hepatomegaly, hepatitis, and signs of liver failure and 3) plotting of the systolic and diastolic blood pressure on the centile charts based on age and stature

Treatment of Manifestations

Treatment recommendations may be separated into two scenarios: 1) treatment for rapid control of hyperammonemia during metabolic decompensations and 2) interval therapy to prevent the primary manifestations and long term complications.

Treatment of acute metabolic decompensations

During acute hyperammonemic episodes severe enough to cause neurological symptoms, the treatment includes 1) discontinuing oral protein intake, 2) supplementing oral intake with intravenous lipids, glucose and intravenous insulin if needed (with close monitoring of blood glucose) to promote anabolism and 3) Intravenous nitrogen scavenging therapy 46

Intravenous nitrogen scavenging therapy involves a loading dose of 600 mg/kg L-arginine-HCL and 250 mg/kg each of sodium benzoate and sodium phenylacetate in 25 to 35 mL/kg of 10% dextrose solution given intravenously over a 90-minute period. This is followed by a sustained intravenous infusion of 600 mg/kg L-arginine-HCL and 250 mg/kg each of sodium benzoate and sodium phenylacetate over a 24-hour period. When available, plasma concentrations of ammonia scavenging drugs should be monitored to avoid toxicity. In the absence of drug levels, a serum anion gap of >15 mEq/L and an anion gap that has risen >6 mEq/L could indicate drug accumulation and increased risk for toxicity.

Ammonia levels usually normalize with therapy; however failure to decrease ammonia levels with medical therapy mandates prompt institution of hemodialysis.Hemodialysis is the preferred method for rapid reduction of ammonia in patients who do not respond to nitrogen scavenging therapy. Continuous arteriovenous hemodialysis (CAVHD) or continuous venovenous hemodialysis (CVVHD) with flow rates >40 to 60 mL/min is optimal. Some centers use extracorporeal membrane oxygenation (ECMO) with hemodialysis. Although this combination of techniques provides very high flow rates (170 to 200 mL/min) and rapidly reduces ammonia levels, morbidity is greater because of the need for surgical vascular access. Nitrogen scavenging therapy needs to be continued during hemodialysis.

Prevention of Primary Manifestations

Dietary restriction of protein and dietary supplementation with arginine are the mainstays in the long term management.

Diet

Lifelong dietary management is necessary and requires the services of a metabolic nutritionist. The Recommended Daily Allowance (RDA) for dietary protein is higher than the minimum needed for normal growth and, hence, most children with UCDs can receive less than the RDA of protein and still maintain adequate growth. Plasma concentrations of ammonia, branched chain amino acids, arginine plasma total protein and serum albumin levels should be maintained within normal ranges. Plasma glutamine concentration should be maintained at less than 1000 micromoles/L if possible 3.

Some of the correlations between compliance with the prescribed diet and outcome are contradictory. Although in some patients dietary therapy along with arginine supplementation have been shown to reverse the abnormalities of hair, to improve cognitive outcome, and to reverse abnormalities on EEG 8,47, 48, in many, dietary therapy has not been shown to influence the outcome of liver disease or cognitive impairment 7, 9.

Arginine base supplementation

The doses of arginine base routinely recommended are 400–700 mg/kg/day in persons weighing less than 20 kg and 8.8–15.4 gm/m2 BSA/day in those weighing more than 20 kg. Supplementation with arginine base helps replenish this amino acid which is deficient in persons with ASLD and promote excretion of nitrogen through the urea cycle as argininosuccinate. Arginine base is preferred for long term chronic treatment as the long term use of arginine hydrochloride may lead to hyperchloremic acidosis.

Arginine base supplementation has been shown to reverse the hair changes; however, its efficacy in preventing the chronic complications is not known. While evidence suggests that arginine base supplementation may prevent metabolic decompensations in those with severe early onset disease, long term follow up of persons identified through newborn screening programs did not detect a difference in outcomes between those who were supplemented with arginine base and those who were not 49,8,9. As the renal clearance of argininosuccinic acid is high, increasing its production through arginine supplementation effectively increases waste nitrogen disposal thereby decreasing the risk of hyperammonemia. However, because of theoretical risk of argininosuccinic acid toxicity on hepatocytes, reducing the amount of supplemental arginine by initiating nitrogen scavenging therapy may have merits.

Oral nitrogen scavenging therapy

Patients who have had frequent metabolic decompensations or episodes of elevated ammonia despite being on a protein restricted diet and arginine base supplementation are candidates for oral nitrogen scavenging therapy, an alternative pathway therapy in which sodium benzoate and sodium phenyl butyrate stimulate the excretion of nitrogen in the form of hippuric acid and phenylacetylglutamine, respectively 49. The dose of sodium phenyl butyrate is 400–600 mg/kg/day for persons weighing up to 20 kg and 9–13 g/m2/day for those weighing more than 20 kg; the dose of sodium benzoate is 250–500mg/kg/day.

Orthotopic liver transplantation (OLT)

Long term correction of ASLD in the liver can be accomplished by OLT50 which has resulted in “biochemical cure” 5153. However, OLT does not correct the arginine deficiency or elevation of argininosuccinic acid in other tissues which are thought to account for the long term complications of ASLD. Thus, we have recommended OLT only in patients with recurrent hyperammonemia or metabolic decompensations that are resistant to conventional medical therapy, or in patients who develop cirrhosis with associated metabolic decompensations.

Prevention of Secondary Complications

Recommendations for salt restriction and use of antihypertensive therapy in those with elevated blood pressures are not different from that in the general population. Potassium supplementation must be considered in those with hypokalemia.

Surveillance

Regular monitoring of the concentration of plasma amino acids to identify deficiency of essential amino acids as well as impending hyperammonemia is essential. The appropriate intervals for monitoring depend on the clinical scenario, but need to be more frequent in neonates and in those with frequent metabolic decompensations. We prefer to evaluate neonates every 1–2 weeks, infants who are between the ages of two months and one year every 1–3 months, and children over age two years every 3–4 months. Early signs of impending hyperammonemic episodes in older individuals include mood changes, headache, lethargy, nausea, vomiting, refusal to feed, ankle clonus, and elevated plasma concentrations of glutamine, alanine and glycine. Plasma glutamine concentration may rise 48 hours in advance of increases in plasma ammonia concentration in such individuals. Annual measurement of blood pressure using the appropriate sized cuff and plotting of the centile values for age and stature would be important for diagnosing those with hypertension. Periodic evaluation of liver function tests and serum electrolytes may be necessary.

Agents/Circumstances to Avoid

The well known precipitants for catabolism and/or hyperammonemia such as excess protein intake, prolonged fasting or starvation, intravenous steroids are to be avoided. Valproic acid can precipitate liver failure and is best avoided in these patients.

GENETIC COUNSELING

ASLD is inherited in an autosomal recessive manner. The parents of an affected individual are obligate heterozygotes and are asymptomatic. At conception, each sib of an affected individual has a 25% chance of being affected. Though the phenotypic manifestations can be variable, in families with one child with the severe neonatal onset form, subsequent children are likely to have the severe neonatal onset form. In contrast, the phenotype of late-onset forms associated with partial ASL enzyme activity is variable.

Carrier Detection

Carrier testing for at-risk family members is possible if the disease-causing mutations in the family have been identified. Carrier testing is not available by biochemical methods.

Acknowledgments

This work was supported by the NIH (DK54450, RR19453, RR00188, GM90310 to BL, GM07526, and DK081735 to AE). AE was supported by a NUCDF fellowship. SCSN is supported by a fellowship grant by the NUCDF and the LCRC from the Osteogenesis Imperfecta Foundation. We acknowledge and thank the clinical efforts of Mary Mullins, Susan Carter, Alyssa Tran, Janice Stuff, and the TCH General Clinical Research Center nursing staff.

This work was supported by fellowship grant from NUCDF (SNSC), NIH DK081735 (AE) and NIH DK54450, RR19453, RR00188, GM90310, GM07526 (BL).

References

1. SW, Brusilow ALH. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001.
2. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127–170. [PubMed]
3. Brusilow SW, Horwich AL. Online Metabolic and Molecular Basis of Inherited Disease. 2009
4. Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008 Aug;94(4):397–402. [PMC free article] [PubMed]
5. Allan JD, Cusworth DC, Dent CE, Wilson VK. A disease, probably hereditary characterised by severe mental deficiency and a constant gross abnormality of aminoacid metabolism. Lancet. 1958 Jan 25;1(7013):182–187. [PubMed]
6. Saudubray JM, Touati G, Delonlay P, et al. Liver transplantation in urea cycle disorders. Eur J Pediatr. 1999 Dec;158( Suppl 2):S55–59. [PubMed]
7. Mori T, Nagai K, Mori M, et al. Progressive liver fibrosis in late-onset argininosuccinate lyase deficiency. Pediatr Dev Pathol. 2002 Nov-Dec;5(6):597–601. [PubMed]
8. Ficicioglu C, Mandell R, Shih VE. Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening. Mol Genet Metab. 2009 Nov;98(3):273–277. [PMC free article] [PubMed]
9. Mercimek-Mahmutoglu S, Moeslinger D, Haberle J, et al. Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab. May;100(1):24–28. [PubMed]
10. Billmeier GJ, Jr, Molinary SV, Wilroy RS, Jr, Duenas DA, Brannon ME. Argininosuccinic aciduria: investigation of an affected family. J Pediatr. 1974 Jan;84(1):85–89. [PubMed]
11. Zimmermann A, Bachmann C, Baumgartner R. Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med. 1986 Feb;110(2):136–140. [PubMed]
12. Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: A result of nitric oxide deficiency? Mol Genet Metab. 2009 Sep-Oct;98(1–2):195–197. [PMC free article] [PubMed]
13. Fichtel JC, Richards JA, Davis LS. Trichorrhexis nodosa secondary to argininosuccinicaciduria. Pediatr Dermatol. 2007 Jan-Feb;24(1):25–27. [PubMed]
14. Brosnan ME, Brosnan JT. Orotic acid excretion and arginine metabolism. J Nutr. 2007 Jun;137(6 Suppl 2):1656S–1661S. [PubMed]
15. Gerrits GP, Gabreels FJ, Monnens LA, et al. Argininosuccinic aciduria: clinical and biochemical findings in three children with the late onset form, with special emphasis on cerebrospinal fluid findings of amino acids and pyrimidines. Neuropediatrics. 1993 Feb;24(1):15–18. [PubMed]
16. O’Brien WE, McInnes R, Kalumuck K, Adcock M. Cloning and sequence analysis of cDNA for human argininosuccinate lyase. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7211–7215. [PubMed]
17. Trevisson E, Salviati L, Baldoin MC, et al. Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Hum Mutat. 2007 Jul;28(7):694–702. [PubMed]
18. Yu B, Howell PL. Intragenic complementation and the structure and function of argininosuccinate lyase. Cell Mol Life Sci. 2000 Oct;57(11):1637–1651. [PubMed]
19. Turner MA, Simpson A, McInnes RR, Howell PL. Human argininosuccinate lyase: a structural basis for intragenic complementation. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9063–9068. [PubMed]
20. Vallee F, Turner MA, Lindley PL, Howell PL. Crystal structure of an inactive duck delta II crystallin mutant with bound argininosuccinate. Biochemistry. 1999 Feb 23;38(8):2425–2434. [PubMed]
21. Wistow G, Piatigorsky J. Recruitment of enzymes as lens structural proteins. Science. 1987 Jun 19;236(4808):1554–1556. [PubMed]
22. Yeh LS, Elzanowski A, Hunt LT, Barker WC. Homology of delta crystallin and argininosuccinate lyase. Comp Biochem Physiol B. 1988;89(2):433–437. [PubMed]
23. Linnebank M, Tschiedel E, Haberle J, et al. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet. 2002 Oct;111(4–5):350–359. [PubMed]
24. Kleijer WJ, Garritsen VH, Linnebank M, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis. 2002 Sep;25(5):399–410. [PubMed]
25. Al-Sayed M, Alahmed S, Alsmadi O, et al. Identification of a common novel mutation in Saudi patients with argininosuccinic aciduria. J Inherit Metab Dis. 2005;28(6):877–883. [PubMed]
26. Wu G, Morris SM., Jr Arginine metabolism: nitric oxide and beyond. Biochem J. 1998 Nov 15;336( Pt 1):1–17. [PubMed]
27. Windmueller HG, Spaeth AE. Source and fate of circulating citrulline. Am J Physiol. 1981 Dec;241(6):E473–480. [PubMed]
28. Mori M, Gotoh T. Arginine metabolic enzymes, nitric oxide and infection. J Nutr. 2004 Oct;134(10 Suppl):2820S–2825S. discussion 2853S. [PubMed]
29. Cui R, Iso H, Pi J, et al. Metabolic syndrome and urinary cGMP excretion in general population. Atherosclerosis. 2006 Mar 22; [PubMed]
30. Vukosavljevic N, Jaron D, Barbee KA, Buerk DG. Quantifying the L-arginine paradox in vivo. Microvasc Res. 2006 Jan;71(1):48–54. [PubMed]
31. Erez ANS, Shchelochkov OA, Premkumar MH, Campeau PM, Chen YC, Garg HK, Li L, Mian A, Bertin TK, Black JO, Zeng H, Tang Y, Reddy AK, Summar M, O’Brien WE, Harrison DG, Mitch WE, Marini JCAJ, Bryan NS, Lee B. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nature Medicine. In press. [PMC free article] [PubMed]
32. Nagasaka H, Tsukahara H, Yorifuji T, et al. Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects. Metabolism. 2009 Mar;58(3):278–282. [PubMed]
33. Pignitter M, Gorren AC, Nedeianu S, Schmidt K, Mayer B. Inefficient spin trapping of superoxide in the presence of nitric-oxide: implications for studies on nitric-oxide synthase uncoupling. Free Radic Biol Med. 2006 Aug 1;41(3):455–463. [PubMed]
34. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992 Nov;59(5):1609–1623. [PubMed]
35. Aoyagi K. Inhibition of arginine synthesis by urea: a mechanism for arginine deficiency in renal failure which leads to increased hydroxyl radical generation. Mol Cell Biochem. 2003 Feb;244(1–2):11–15. [PubMed]
36. Aoyagi K, Shahrzad S, Iida S, et al. Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. Kidney Int Suppl. 2001 Feb;78:S93–96. [PubMed]
37. D’Hooge R, Pei YQ, Marescau B, De Deyn PP. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice. J Neurol Sci. 1992 Oct;112(1–2):96–105. [PubMed]
38. Keskinen P, Siitonen A, Salo M. Hereditary urea cycle diseases in Finland. Acta Paediatr. 2008 Oct;97(10):1412–1419. [PubMed]
39. Haberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn. 2004 May;24(5):378–383. [PubMed]
40. Kleijer WJ, Garritsen VH, van der Sterre ML, Berning C, Haberle J, Huijmans JG. Prenatal diagnosis of citrullinemia and argininosuccinic aciduria: evidence for a transmission ratio distortion in citrullinemia. Prenat Diagn. 2006 Mar;26(3):242–247. [PubMed]
41. Kamoun P, Fensom AH, Shin YS, et al. Prenatal diagnosis of the urea cycle diseases: a survey of the European cases. Am J Med Genet. 1995 Jan 16;55(2):247–250. [PubMed]
42. Mandell R, Packman S, Laframboise R, et al. Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Prenat Diagn. 1996 May;16(5):419–424. [PubMed]
43. Pijpers L, Kleijer WJ, Reuss A, et al. Transabdominal chorionic villus sampling in a multiple pregnancy at risk of argininosuccinic aciduria: a case report. Am J Med Genet. 1990 Aug;36(4):449–450. [PubMed]
44. Engel H, Drach J, Keyhani A, et al. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia. 1999;13(4):568–577. [PubMed]
45. Trevisson E, Burlina A, Doimo M, et al. Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. J Biol Chem. 2009 Oct 16;284(42):28926–28934. [PubMed]
46. Consensus statement from a conference for the management of patients with urea cycle disorders. J Pediatr. 2001 Jan;138(1 Suppl):S1–5. [PubMed]
47. Kvedar JC, Baden HP, Baden LA, Shih VE, Kolodny EH. Dietary management reverses grooving and abnormal polarization of hair shafts in argininosuccinase deficiency. Am J Med Genet. 1991 Aug 1;40(2):211–213. [PubMed]
48. Coryell ME, Hall WK, Thevaos TG, et al. A familial study of a human enzyme defect, argininosuccinic aciduria. Biochem Biophys Res Commun. 1964;14:307–312. [PubMed]
49. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: Twenty years later. Journal of Pediatrics. 2001 Jan;138(1):S46–S54. [PubMed]
50. Lee B, Goss J. Long-term correction of urea cycle disorders. Journal of Pediatrics. 2001 Jan;138(1):S62–S71. [PubMed]
51. Robberecht E, Maesen S, Jonckheere A, Van Biervliet S, Carton D. Successful liver transplantation for argininosuccinate lyase deficiency (ASLD) J Inherit Metab Dis. 2006 Feb;29(1):184–185. [PubMed]
52. Marble M, McGoey RR, Mannick E, et al. Living related liver transplant in a patient with argininosuccinic aciduria and cirrhosis: metabolic follow-up. J Pediatr Gastroenterol Nutr. 2008 Apr;46(4):453–456. [PubMed]
53. Newnham T, Hardikar W, Allen K, et al. Liver transplantation for argininosuccinic aciduria: clinical, biochemical, and metabolic outcome. Liver Transpl. 2008 Jan;14(1):41–45. [PubMed]